Results 171 to 180 of about 24,603 (322)

Correction: SSNdesign-An R package for pseudo-Bayesian optimal and adaptive sampling designs on stream networks. [PDF]

PLoS One
Pearse AR, McGree JM, Som NA, Leigh C, Maxwell P, Ver Hoef JM, Peterson EE.   +6 more
europepmc   +1 more source

Optimal PI$^{{\lambda}}$ D$^{{\mu}}$ Controller Design for Two Wheeled Inverted Pendulum

, 2018
Hüseyin Oktay Erkol
openalex   +1 more source

D.3.3 HiL testing of optimal control and energy dispatching strategy

, 2021
Daniel Stahleder, Marko Jelić, James W. Freeman, Laura Zabala, Lluis Millet Biosca, Noel Ryan   +5 more
openalex   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Environmental dynamics impact whether matching is optimal. [PDF]

PNAS Nexus
Guo Y, Hermundstad AM.
europepmc   +1 more source

The optimal dose of vitamin D in growing girls during academic years: a randomized trial

, 2011
MEHRDAD SHAKINBA, Tefagh Samane, Zahra Nafei   +2 more
openalex   +2 more sources

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

The role of feedback for sensorimotor decisions under risk. [PDF]

J Vis
Wolf C, Belopolsky AV, Lappe M.
europepmc   +1 more source

TREX1, a predator for treating MSI‐H tumors?

Molecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya, Joséphine Deneft, Marc Van den Eynde   +2 more
wiley   +1 more source

A novel Bayesian method for dual-agent Phase I dose-escalation studies using penalized D-optimality [PDF]

Trials, 2013
Wheeler G.
europepmc   +1 more source